2025
Impact of SARS-CoV-2 on healthcare and essential workers: A longitudinal study of PROMIS-29 outcomes
Dorney J, Mannan I, Malicki C, Wisk L, Elmore J, O’Laughlin K, Morse D, Gatling K, Gottlieb M, Santangelo M, L’Hommedieu M, Gentile N, Saydah S, Hill M, Huebinger R, Martin K, Idris A, Kean E, Schaeffer K, Rodriguez R, Weinstein R, Spatz E, Group F. Impact of SARS-CoV-2 on healthcare and essential workers: A longitudinal study of PROMIS-29 outcomes. PLOS ONE 2025, 20: e0324755. PMID: 40680016, PMCID: PMC12273909, DOI: 10.1371/journal.pone.0324755.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesGeneral workersPhysical health summary scoreNon-HCWsEssential workersHealth summary scoresLong-term physical healthFrontline workersAssociated with high job stressLongitudinal studyCognitive functionHigh job stressHigher cognitive scoresEmployment typePROMIS-29Physical healthSummary scoreMain OutcomesINSPIRE registrySARS-CoV-2 statusGEE modelMandatory serviceSARS-CoV-2 exposureCognitive scoresJob stressNirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial
Sawano M, Bhattacharjee B, Caraballo C, Khera R, Li S, Herrin J, Christian D, Coppi A, Warner F, Holub J, Henriquez Y, Johnson M, Goddard T, Rocco E, Hummel A, Mouslmani M, Hooper W, Putrino D, Carr K, Charnas L, De Jesus M, Nepert D, Abreu P, Ziegler F, Spertus J, Iwasaki A, Krumholz H. Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial. The Lancet Infectious Diseases 2025, 25: 936-946. PMID: 40188838, DOI: 10.1016/s1473-3099(25)00073-8.Peer-Reviewed Original ResearchPhysical health summary scoreBaseline to dayAdverse eventsNirmatrelvir-ritonavirSARS-CoV-2 infectionDouble-blindStudy drug-related treatment-emergent adverse eventsDrug-related treatment-emergent adverse eventsTreatment-emergent adverse eventsIntention-to-treat populationWeek 6Baseline to week 6Documented SARS-CoV-2 infectionActive liver diseaseEffective pharmacological interventionsLong COVIDAcute medical illnessSafety populationPatient-Reported Outcomes Measurement Information SystemEarly treatment terminationRenal impairmentTreat long-COVIDPlacebo-ControlledEfficacy endpointRandomised controlled trials
2017
Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study
Batt K, Recht M, Cooper D, Iyer N, Kempton C. Construct validity of patient-reported outcome instruments in US adults with hemophilia: results from the Pain, Functional Impairment, and Quality of life (P-FiQ) study. Patient Preference And Adherence 2017, 11: 1369-1380. PMID: 28860720, PMCID: PMC5558590, DOI: 10.2147/ppa.s141390.Peer-Reviewed Original ResearchPatient-reported outcome instrumentsPatient-reported outcomesSF-36v2Physical functionBodily painSelf-CareQuality of lifePain domainUsual activitiesConstruct validityEQ-5D-5L mobilityPhysical health summary scoreEQ-5D-5L pain/discomfortHistory of joint pain/bleedingSF-36v2 Physical FunctioningHealth-related quality of lifeLower-extremity activitiesFunctional impairmentDisease-specific patient-reported outcomeHealth summary scoresPhysical health summaryBPI pain interferenceHealth-related qualityPearson product-moment correlation coefficientProduct-moment correlation coefficient
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply